Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Media
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsShorts
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

“Multiple Myeloma Talk”: A Review of Data from the ASH 2020 Virtual Meeting

EP. 1: Updates in Multiple Myeloma in the Frontline Setting

ByAjai Chari, MD, Mount Sinai Hospital,Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center,Saad Z. Usmani, MD, FACP, Levine Cancer Institute,Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens
January 29th 2021

EP. 2: Updates in Relapsed/Refractory Myeloma

ByAjai Chari, MD, Mount Sinai Hospital,Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center,Saad Z. Usmani, MD, FACP, Levine Cancer Institute,Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens
January 29th 2021

EP. 3: Third and Subsequent Line Options for Multiple Myeloma

ByAjai Chari, MD, Mount Sinai Hospital,Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center,Saad Z. Usmani, MD, FACP, Levine Cancer Institute,Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens
January 29th 2021
Advertisement
Advertisement

Trending on OncLive

1

FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC

2

PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings

3

Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL

4

Olverembatinib Plus Blinatumomab Yields High Early-Phase CR/CRi Rates in R/R Ph+ CML and B-ALL

5

META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us